Showing results (131-140 of 150) with videos related to

Sort By:
Pageof 15
The New England Journal of Medicine|October 22, 2025
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder CancerThomas Powles, Ariel G Kann, Daniel Castellano, et al.
Frontiers in Immunology|July 22, 2024
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 studyMartina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2024
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 studyCarlo Messina, Martina Catalano, Giandomenico Roviello, et al.
Frontiers in Oncology|March 6, 2026
Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 studyFrancesco Pantano, Andrea Malgeri, Ugo De Giorgi, et al.
The Oncologist|August 1, 2020
Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise CentersLucia Nappi, Margaret Ottaviano, Pasquale Rescigno, et al.
Journal of Translational Medicine|September 30, 2022
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 studySara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, et al.
Frontiers in Oncology|October 10, 2022
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysisSara Elena Rebuzzi, Alessio Signori, Marco Stellato, et al.
Scientific Reports|June 17, 2026
Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysisBrigida Anna Maiorano, Giandomenico Roviello, Alessandro Rizzo, et al.
European Journal of Cancer (Oxford, England : 1990)|August 6, 2021
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trialOrazio Caffo, Cinzia Ortega, Franco Nolè, et al.
Clinical Genitourinary Cancer|November 27, 2024
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 StudyBrigida Anna Maiorano, Martina Catalano, Chiara Mercinelli, et al.
Pageof 15